<DOC>
	<DOC>NCT00472953</DOC>
	<brief_summary>This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description>The decision to discontinue the development of AERxÂ® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Chronic Obstructive Pulmonary Disease Type 1 or type 2 diabetes HbA1c lower or equal to 11.0 % Body Mass Index (BMI) lower or equal to 40.0 kg/m2 Recurrent severe hypoglycaemia Current smoking or smoking within the last 6 months Other pulmonary disease including asthma Proliferative retinopathy or maculopathy requiring acute treatment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>